Charity profile · Historical source record

Drugs for Neglected Diseases Initiative North America

Historical collection: May 2019 · Rating details mostly from 2017. Source & context

The mission

What this organization describes

Developing new drugs for patients suffering from the most neglected communicable diseases

The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.

Mission and tagline reproduced from the source record.

Historical scorecard

Three perspectives. One record.

84.44Overall score
out of 100

78.37Financial score
out of 100

96.00Accountability & transparency
out of 100

These are the dataset’s historical numeric fields, not a current rating or a new DonorAPI.com assessment. Read the score context ↗

Financial context

Revenue, expenses, and composition

Total revenue · USD$4,208,499

Total expenses · USD$4,091,229

Program expenses

$3,244,344.60 recorded amount

79.3%

Fundraising expenses

$605,501.89 recorded amount

14.8%

Administrative expenses

$233,200.05 recorded amount

5.7%

Fundraising efficiency: $0.14 spent per $1 raised in donations, as defined in the source.

Expense shares are displayed as percentages. Component amounts in this collection match total expenses multiplied by the source ratios; rounding can leave a small difference from the total. The source does not supply a row-specific fiscal year. Field definitions ↗

Historical leadership record

The leadership information supplied

Recorded leader: Rachel Cohen
Recorded compensation: $167,574.00
Recorded compensation percentage: 4.09%

These fields do not establish the current officeholder or current compensation. The metadata does not specify the denominator of the leader compensation percentage. Read with context ↗

Inspect all 23 original source fields

Exact source strings are retained below, including numeric precision. A blank value is marked as not reported; zero remains zero.

All 23 original fields for Drugs for Neglected Diseases Initiative North America
Source field	Original source value
`ascore` Accountability & transparency score	96.0
`category` Category	Health
`description` Mission & description	The mission of Drugs for Neglected Diseases Initiative North America (DNDi NA) is to develop new drugs, or new formulations of existing drugs, for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected diseases or development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address.
`ein` EIN	20-8774179
`tot_exp` Total expenses	4091229.0
`admin_exp_p` Administrative expense fraction	0.057
`fund_eff` Fundraising efficiency ($ per $1 raised)	0.14
`fund_exp_p` Fundraising expense fraction	0.14800000000000002
`program_exp_p` Program expense fraction	0.7929999999999999
`fscore` Financial score	78.37
`leader` Recorded leader	Rachel Cohen
`leader_comp` Recorded leader compensation	167574.0
`leader_comp_p` Recorded leader compensation fraction	0.0409
`motto` Tagline	Developing new drugs for patients suffering from the most neglected communicable diseases
`name` Charity name	Drugs for Neglected Diseases Initiative North America
`tot_rev` Total revenue	4208499.0
`score` Overall score	84.44
`state` State code	NY
`subcategory` Subcategory	Medical Research
`size` Source size label	mid
`program_exp` Program expenses	3244344.5969999996
`fund_exp` Fundraising expenses	605501.8920000001
`admin_exp` Administrative expenses	233200.053

Identity & classification

At a glance

EIN: 20-8774179
Source category: Health
Source subcategory: Medical Research
Recorded location: New York (NY)
Expense-based size: Mid-sized
$3.5M–$13.5M in total expenses · source label: mid

Explore alongside

Related source records

Linked by source subcategory, prioritizing the same recorded state. Not a recommendation or ranking.

A useful next step

Keep the context.

Check current organizational information separately before making a giving decision. This record does not include an official website, donation URL, or current eligibility field.

Giving research guide ↗

Source: Charity Navigator Scores Expenses Dataset, version 1, attributed to katyjqian on Kaggle. Collection: May 2019; rating details mostly from 2017. Read attribution, scope, and reuse notes.